A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Sacituzumab govitecan (Primary) ; Docetaxel; Paclitaxel; Vinflunine
- Indications Urogenital cancer
- Focus Registrational; Therapeutic Use
- Acronyms TROPiCS-04
- Sponsors Gilead Sciences; Immunomedics
Most Recent Events
- 30 Jan 2025 Planned End Date changed from 1 Jul 2025 to 1 Oct 2025.
- 30 Jan 2025 Planned primary completion date changed from 1 Jul 2025 to 1 Oct 2025.
- 20 Sep 2024 Planned End Date changed from 1 Oct 2024 to 1 Jul 2025.